REALM IDX - Key Persons

Job Titles:

• Member of the Board of Directors
• Member of the Board of Directors of Invicro

Dr. Gregory Sorensen has been a member of the board of directors of Invicro since January 2018 and has been a consultant advising KMI on the strategic and scientific aspects of KMI's global health care business since June 2016. He has been the Chief Executive Officer and co-founder of DeepHealth (now the AI division of RadNet) since October 2015 and previously served as the President and Chief Executive Officer of Siemens Healthcare North America from June 2011 to September 2015. Read more + Prior to Siemens, he served as a neuroradiologist, physician scientist, and professor at Massachusetts General Hospital and Harvard Medical School. Dr. Sorensen has served as a supervisory board member for Fresenius Medical Care since May 2021, a supervisory board member of Siemens Healthineers since March 2018, and the executive chairman of IMRIS Deerfield Imaging since October 2015. He also works with other emerging healthcare businesses. Dr. Sorensen served as a board member of the nonprofit Research!America until March 2020, and as an Advisory Council member to the nonprofit National Institute of Biomedical Imaging and Bioengineering until February 2019. He earned a B.S. in Biology in 1984 from California Institute of Technology, an M.S. in Computer Science in 1987 from Brigham Young University, and an M.D. in 1989 from Harvard Medical School. Show less -

Job Titles:

• Public Relations

Job Titles:

• Member of the Executive Team
• SVP, Human Resources

Catherine Suh has served as our SVP, Human Resources since December 2021. Prior to that, she served as the Vice President of People at Ambry Genetics. She joined in 2016 during a time of hypergrowth for the company to implement a scalable infrastructure that could support a dynamically growing organization. Prior to Ambry, she was a HR Business Partner at Experian Consumer Services and was involved in several acquisitions and a divestiture. For nearly 15 years, Catherine has worked in highly regulated environments in healthcare, financial technology and biotech. She has worked closely alongside leaders during times of growth and transformation to align the HR strategy with the business strategy. Catherine earned an MBA and a bachelor's degree in Psychology from the University of California, Irvine.

Job Titles:

• Chief Compliance Officer
• Member of the Executive Team

Craig Clesson brings over 15 years' experience as a compliance professional and a life sciences attorney supporting publicly traded healthcare, biotechnology, and pharmaceutical companies. Most recently, Craig was Compliance Officer at 1Life Healthcare/One Medical, an integrated national primary care practice and digital health technology company, where he oversaw the corporate, healthcare, and data privacy compliance programs. Prior to that, Craig was Ethics and Compliance Officer at Aegerion Pharmaceuticals, a small biopharmaceutical company focusing on ultrarare diseases with operations in the U.S., Europe, and Latin America. Read more + Earlier roles included oversight of compliance diligence and integration activities supporting business development at Amgen and advising on product portfolio lifecycle management at King Pharmaceuticals, a mid-sized pharmaceutical company. A Certified Information Privacy Professional (U.S.) and an actively licensed attorney, Craig earned his J.D. from the University of Illinois Chicago School of Law. Show less -

Job Titles:

• Chief Executive Officer
• Member of the Board of Directors
• Member of the Executive Team
• President

Dr. Elliott has served as our Chief Executive Officer and President since May 2021, has been a member of the Board of Directors of Ambry since October 2017, and previously served as Chief Executive Officer of Ambry from 2016 until May 2021. Aaron joined Ambry in 2008 as a scientist in the research and development department working closely on the development of comprehensive molecular diagnostic tests. An innovator in complex genetic testing, Aaron has been involved in the conception and implementation of many of the diagnostics industry's first-to-market tests and technologies, including the first commercial NGS assay, CLIA/CAP Exome test and hereditary cancer panels among others. Dr. Aaron Elliott has served as our Chief Executive Officer and President since May 2021, has been a member of the Board of Directors of Ambry since October 2017 and previously served as Chief Executive Officer of Ambry from 2016 until May 2021. Aaron joined Ambry in 2008 as a scientist in the research and development department working closely on the development of comprehensive molecular diagnostic tests. An innovator in complex genetic testing, Aaron has been involved in the conception and implementation of many of the diagnostic industry first-to-market tests and technologies including the first commercial NGS assay, CLIA/CAP Exome test, and hereditary cancer panels among others. Read more + Aaron helped guide Ambry through extreme periods of growth, including its acquisition by Konica Minolta PM, Inc. Over the years, he has held many leadership positions at Ambry, including Director of Genomic Services, Chief Operating Officer, and Chief Scientific Officer. Aaron began his career as a Postdoctoral Fellow at the Novartis Institute of Functional Genomics in San Diego, where he conducted research on potential drug targets for chemotherapeutic resistance and tumor formation. As part of this research, he helped in identifying the first mitochondrial ABC transporter in cancer cells, which are responsible for multi-drug resistance in many solid tumors. A graduate of Franklin and Marshall College with a B.S. in Biology, Aaron conducted his Ph.D. Genetics training at Thomas Jefferson University and The Johns Hopkins University School of Medicine. Show less -

Job Titles:

• Member of the Executive Team
• Chief Strategy and Informatics Officer

Dr. Jonathan Usuka has served as our Chief Strategy and Informatics Officer since August 2021. Prior to joining REALM, he served as Senior Expert in Pharmaceutical and Medical Products at McKinsey & Company from 2016 to 2021. From 2009 to 2015, Jonathan led R&D Informatics at Celgene Corporation, contributing to adaptive clinical studies and genetic biomarkers in oncology and immunology resulting in major label expansions and new therapeutic approvals. Read more + He served as Senior Director, Life Science Marketing at Accelrys from 2008 to 2009. Jonathan also served as Director of Global R&D Information from 2006 to 2008 and Associate Director of Genome Informatics from 2001 to 2006 at Roche Pharmaceuticals, a global pioneer in pharmaceuticals and diagnostics. From 1994 to 2001, Jonathan served as Chief Executive Officer of Ubi. He earned his B.A. from Princeton University in 1992, an M.B.A. in 2008 from The Wharton School, University of Pennsylvania, and a Ph.D. in Chemistry from Stanford University in 2001. Show less -

Job Titles:

• Chief Financial Officer
• Member of the Executive Team

Dr. Chen has served as our Chief Financial Officer since September 2021. Prior to joining REALM, Dr. Chen served as the Chief Financial Officer of Thermo Fisher Scientific's Transplant Diagnostics Business from November 2017 to September 2021. From 2015-2017 he was a consultant for the life science, manufacturing and aerospace industries. From 2013 to 2015 Dr. Chen served as the VP of M&A/Business Development at Response Genetics. From 2010-2012, he served as the Chief Financial Officer and Vice President of Finance at Meggitt Aerospace. Read more + Prior to these roles Dr. Chen served in various senior finance positions at Northrop Grumman and Raytheon. Dr. Chen began his career as a research scientist at the Bioacoustics Research Laboratory at the University of Illinois, where he conducted research on the early detection of breast tumors using ultrasound imaging. As part of his research, Dr. Chen was awarded a 3-year National Institutes of Health Radiation Oncology Fellowship for excellence of research. Dr. Chen also worked in the Biomedical Sciences Division at Lawrence Livermore National Laboratory where he wrote artificial intelligence software for big data automated computer analysis and screening of high-resolution digital mammograms using Fourier/spectral analysis, advanced statistical analytics and image processing. Dr. Chen also worked as a software engineer and program manager at MIT Lincoln Laboratory as a member of the technical staff with a specialty in analytics, signal processing and array imaging. Dr. Chen earned a B.S. in Electrical & Computer Engineering from the University of Illinois at Urbana-Champaign in 1990, an M.S. in Electrical & Computer Engineering from the University of Illinois at Urbana-Champaign in 1992, a Ph.D. in Electrical/Biomedical Engineering from the University of Illinois at Urbana-Champaign in 1995 and an M.B.A. from The University of Chicago Booth School of Business in 2003. Show less -

Job Titles:

• Chief Operating Officer
• Member of the Executive Team

George Abe has served as our Chief Operating Officer since August 2021. Prior to that, he served as Chief Business and Strategy Officer for Invicro, responsible for establishing and growing Invicro's emerging Advanced Pathology Services business and leading the company's global corporate development efforts. George has over 30 years of experience in creating value in the life science and high technology industries. Read more + He has been involved in numerous transactions including mergers, acquisitions, divestitures, and strategic licensing. He has also been the CEO of three life science companies, two of which focused on developing novel imaging solutions for oncology and neuroscience research and diagnostics. George has also served on a variety of private, public, and not-for-profit boards. He holds a bachelor's degree in engineering from Trinity College, a master's degree in engineering from the University of Connecticut and is a graduate of the Greater Boston Executive Program at MIT, Sloan School of Business. Show less -

Job Titles:

• Member of the Board of Directors
• Director of Our Board

Kiyotaka Fujii has served as a Director of our board since October 2018. He served as our President from November 2018 to November 2019, as our Chief Executive Officer from November 2018 to May 2021, and as a Chairman of the Board for both Ambry Genetics and Invicro. In addition, Fujii has been President, Global Healthcare, and Senior Executive Vice-President and Executive Officer of KMI since 2016. Fujii's extensive business career ranges from medical services, information technology, and consumer products to investment banking. Read more + He has held several Japan CEO positions with top global companies since 1997, including SAP, Louis Vuitton, Cadence Design Systems, and Quintiles Transnational. From 2012 to 2015, he served at Olympus as the first independent board member to rebuild its governance and businesses. From 1986 to 1993, Fujii held the role as the first Japanese M&A investment banker in New York with Credit Suisse First Boston and Goldman Sachs. He began his career with McKinsey as the first hire from a Japanese university. As the author of "Global Mind," a top-selling Japanese business book, Fujii is often consulted for his perspective as a global business leader in Japan by the government and news media. He received an M.B.A. from the Harvard Business School in 1986 and a B.A. in Law from the University of Tokyo in 1981. Show less -

Job Titles:

• General Counsel
• Member of the Executive Team
• Secretary
• General Counsel and Secretary of REALM

Michelle Smith is the General Counsel and Secretary of REALM where she oversees all legal and governance matters. Michelle also serves as the General Counsel and Secretary of Ambry Genetics. Prior to joining REALM, Michelle practiced intellectual property law at the international law firm of Jones Day in Irvine, California, and general corporate law at The Patrón Spirits Company in Las Vegas, Nevada. Read more + In law school, she served as an extern for the U.S. Attorney's Office, Central District in Santa Ana, California. Michelle graduated summa cum laude from the University of California Los Angeles. She then earned her J.D. from the University of Southern California where she served on the Southern California Law Review. She is admitted to practice law in the State of California. Show less -

Job Titles:

• Chief Marketing Officer
• Member of the Executive Team

Mickie Henshall has served as our Chief Marketing Officer since September 2021. Prior to that, she served as the Senior Vice President of Marketing at Ambry Genetics, where she was responsible for the corporate brand and marketing strategies. For more than 20 years, Mickie has focused on the health sciences, spanning medical devices, molecular diagnostics, and point-of-care hospital testing. As a change-agent, Mickie has specialized in transforming public and private equity-backed organizations into high-growth commercial companies through her talent in brand creation, portfolio development, and marketing strategy. Read more + As one of the first diagnostics commercial employees at Illumina, her deep understanding of science, regulatory compliance, and commercial execution enabled her to lead Illumina to its first FDA 510(k) and the company's clinical market strategy. Mickie's leadership includes global experience, having led regional marketing teams in Europe, China, and Australia. Her market knowledge has made her an integral member of merger and acquisition teams, most recently through the successful sale of Accriva Diagnostics to Werfen Life, a multi-billion-dollar Spanish IVD company. Henshall earned a B.A. in Integrative Biology from University of California, Berkeley. Show less -

Job Titles:

• Director
• Member of the Board of Directors

Mr. Niklai has served as a director on our board since September 2021 and has been a member of the boards of directors of Ambry and KMP since August 2019. Mr. Niklai has served as Managing Director of both JIC Capital, Ltd. since 2020 and INCJ since 2012. He also serves as a member of the board of directors of INCJ SJ Investment Ltd., a private company, and since August 2021, as a member of the board of directors of Eneti Inc., a public company listed on the New York Stock Exchange. Read more + Mr. Niklai served as a member of the boards of directors of several private companies, including Solar Holdings (Italy) from 2015 to 2016, Landis+Gyr (Switzerland) from 2013 to 2017, Zephyr Corporation (Japan) from 2013 to 2016, AGS (Portugal) from 2017 to 2019, Atlantis Investorco (United Kingdom) from 2017 to 2021, Chaucer Foods (United Kingdom) from 2018 to 2020, and Aguas Nuevas (Chile) from 2018 to 2020. Mr. Niklai also previously worked as a director at Berlitz Corporation from 2010 through 2012. From 2008 to 2009, he was Group Director of Finance/Operations at Shane Corporation Japan. From 2006 to 2008, he was a Sector Specialist at Credit Suisse Securities Japan. Mr. Niklai was a Senior Manager at IT Convergence from 2003 to 2004 and Senior Consultant at Cap Gemini Ernst & Young from 2000 to 2003. Mr. Niklai earned his B.A. in 1995 from Corvinus University of Budapest, an M.A. in Economics in 2000 from Nihon University, and an M.B.A. in 2006 from London Business School. We believe that Mr. Niklai should serve as a member of our board of directors due to his extensive leadership experience including his experience serving on Ambry's board and other boards. Show less -